Literature DB >> 1712704

Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.

S Nattel1.   

Abstract

Classifications of antiarrhythmic drugs have developed because of a need to organize the large number of agents available according to pharmacological properties of clinical relevance. The current classification is a hybrid of classification systems developed in the early 1970s. It subdivides drugs according to 4 major pharmacological actions: (a) depression of phase 0 sodium current; (b) antagonism of adrenergic effects on the heart; (c) prolongation of of action potential duration; and (d) calcium channel blockade. Further subdivision of sodium channel blockers is based on the kinetics of sodium channel blockade and drug effects on action potential duration. A critical analysis of selected aspects of the clinical actions of antiarrhythmic drugs indicates the value of the current classification, as well as some limitations in its ability to separate drugs into distinct groups with characteristic clinical properties. The strengths of the current classification are due to the clinical importance of the pharmacological properties on which it is based. These results in electrophysiological actions, indications, and adverse effects that are typical for each group of drugs. The limitations of the current system relate to the propensity of individual drugs to have actions of more than one class simultaneously, the way that the various actions of a given drug are dependent on concentration, rate, and tissue type, and to problems in subclass definition. Some of these shortcomings could be alleviated by returning to the concept, originally put forward by Singh and Vaughan Williams, of classes of drug action rather than classes of drug per se. This approach would be pharmacologically more realistic than trying to assign each antiarrhythmic agent to a single unique class, would be better able to incorporate the complexities of drug action, and would potentially be more flexible. The wide use of antiarrhythmic drug classifications attests to their value, and suggests that they are likely to continue to be important in the future.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712704     DOI: 10.2165/00003495-199141050-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  261 in total

1.  Disopyramide.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1979-04-26       Impact factor: 91.245

2.  Effect of lidocaine on conduction in canine Purkinje fibers and at the ventricular muscle-Purkinje fiber junction.

Authors:  J T Bigger; W J Mandel
Journal:  J Pharmacol Exp Ther       Date:  1970-04       Impact factor: 4.030

3.  Electrophysiologic and clinical effects of intravenous and oral encainide in patients with Wolff-Parkinson-White syndrome and paroxysmal atrial fibrillation.

Authors:  M Chimienti; M Moizi; J A Salerno; C Klersy; L Guasti; M Previtali; E Marangoni; C Montemartini; P Bobba
Journal:  Eur Heart J       Date:  1987-03       Impact factor: 29.983

4.  Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram.

Authors:  G Steinbeck; P Bach; R Haberl
Journal:  J Am Coll Cardiol       Date:  1986-10       Impact factor: 24.094

5.  Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone.

Authors:  J W Mason; L M Hondeghem; B G Katzung
Journal:  Circ Res       Date:  1984-09       Impact factor: 17.367

6.  Sudden death in hospitalized patients: cardiac rhythm disturbances detected by ambulatory electrocardiographic monitoring.

Authors:  I P Panidis; J Morganroth
Journal:  J Am Coll Cardiol       Date:  1983-11       Impact factor: 24.094

7.  Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone.

Authors:  B McGovern; H Garan; R F Malacoff; J P DiMarco; G Grant; T D Sellers; J N Ruskin
Journal:  Am J Cardiol       Date:  1984-06-01       Impact factor: 2.778

8.  Limited role of intravenous propafenone hydrochloride in the treatment of sustained ventricular tachycardia: electrophysiologic effects and results of programmed ventricular stimulation.

Authors:  J U Doherty; H L Waxman; M G Kienzle; D M Cassidy; F E Marchlinski; A E Buxton; M E Josephson
Journal:  J Am Coll Cardiol       Date:  1984-08       Impact factor: 24.094

9.  Mexiletine for control of drug-resistant ventricular tachycardia: clinical and electrophysiologic results in 44 patients.

Authors:  L E Waspe; H L Waxman; A E Buxton; M E Josephson
Journal:  Am J Cardiol       Date:  1983-04       Impact factor: 2.778

10.  Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers.

Authors:  N Ikeda; B N Singh; L D Davis; O Hauswirth
Journal:  J Am Coll Cardiol       Date:  1985-02       Impact factor: 24.094

View more
  9 in total

Review 1.  Cardiovascular drugs.

Authors:  P Vermeij
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

2.  Electrophysiological basis for antiarrhythmic efficacy, positive inotropy and low proarrhythmic potential of (-)-caryachine.

Authors:  M H Wu; M J Su; S S Lee; L T Lin; M L Young
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 3.  Is there a future for antiarrhythmic drug therapy?

Authors:  P G Guerra; M Talajic; D Roy; M Dubuc; B Thibault; S Nattel
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

Review 4.  Novel approaches for pharmacological management of atrial fibrillation.

Authors:  Joachim R Ehrlich; Stanley Nattel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 5.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

6.  Class I and III antiarrhythmic actions of prazosin in guinea-pig papillary muscles.

Authors:  O Pérez; C Valenzuela; E Delpón; J Tamargo
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

7.  Quinidine-induced open channel block of K+ current in rat ventricle.

Authors:  R B Clark; J Sanchez-Chapula; E Salinas-Stefanon; H J Duff; W R Giles
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

8.  Voltage- and time-dependent inhibitory effects on rat aortic and porcine coronary artery contraction induced by propafenone and quinidine.

Authors:  F Pérez-Vizcaíno; B Fernández del Pozo; F Zaragozá; J Tamargo
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

Review 9.  Why translation from basic discoveries to clinical applications is so difficult for atrial fibrillation and possible approaches to improving it.

Authors:  Stanley Nattel; Philip T Sager; Jörg Hüser; Jordi Heijman; Dobromir Dobrev
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 10.787

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.